Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

MicroRNA mediated effects on macrophage activation and disease pathology in steroid-resistant asthma

EF 2010-11

Résumé
In severe asthma, patients often respond poorly to steroid-based therapies. While this subset of patients represents a small portion of asthmatic patients, they account for around 50 percent of all health care expenses associated with asthma in many developed countries (including Canada and Australia). Further, the numbers of patients and the severity of disease has increased dramatically in recent years, resulting in increased health care costs, and decreased quality of life for severe asthmatic patients. The lack of steroid-mediated control of both inflammation and airway hyperresponsiveness (AHR) in these patients suggests a fundamentally different mechanism of disease, compared to the more common moderate for of asthma. However, the direct mechanisms underlying steroid-resistant asthma pathology remain poorly understood and no effective therapies currently exist to treat this population. Release of the small molecule cytokines interferon (IFNg) and IL-27, activation of bacterial (LPS)-induced inflammatory pathways and macrophage activation play key roles in the development of AHR in severe steroid-resistant asthmatics. Dr. Paul Foster's lab recently demonstrated that administration of IFNg and LPS can also induce steroid-resistant neutrophilia and AHR in mice, as a model of human asthma. MicroRNAs (miRNAs) are also molecules that are emerging as regulators of inflammation and preliminary studies suggest they may play a key role in the regulation of airway disease. In my research proposal, I will characterize miRNA expression profiles in the steroid-resistant mouse model, focusing on responses in airway cells and activated immune cells. I will then selectively block specific miRNAs to determine effects on disease severity and cell function, with the aim to identify novel therapies for asthma treatment. Ultimately, our aim is to bring these findings into the clinic and provide a new therapy to treat patients suffering from steroid-resistant asthma.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New South Wales, Australia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
225903
Name
Maltby Steven
Region
New South Wales
Country
Australia
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
MicroRNA mediated effects on macrophage activation and disease pathology in steroid-resistant asthma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Airway Epithelium; Antagomirs; Asthma; Immunology; Inflammation; Macrophages; Microrna; Respiratory Health; Steroid Resistance
Abstract
In severe asthma, patients often respond poorly to steroid-based therapies. While this subset of patients represents a small portion of asthmatic patients, they account for around 50 percent of all health care expenses associated with asthma in many developed countries (including Canada and Australia). Further, the numbers of patients and the severity of disease has increased dramatically in recent years, resulting in increased health care costs, and decreased quality of life for severe asthmatic patients. The lack of steroid-mediated control of both inflammation and airway hyperresponsiveness (AHR) in these patients suggests a fundamentally different mechanism of disease, compared to the more common moderate for of asthma. However, the direct mechanisms underlying steroid-resistant asthma pathology remain poorly understood and no effective therapies currently exist to treat this population. Release of the small molecule cytokines interferon (IFNg) and IL-27, activation of bacterial (LPS)-induced inflammatory pathways and macrophage activation play key roles in the development of AHR in severe steroid-resistant asthmatics. Dr. Paul Foster's lab recently demonstrated that administration of IFNg and LPS can also induce steroid-resistant neutrophilia and AHR in mice, as a model of human asthma. MicroRNAs (miRNAs) are also molecules that are emerging as regulators of inflammation and preliminary studies suggest they may play a key role in the regulation of airway disease. In my research proposal, I will characterize miRNA expression profiles in the steroid-resistant mouse model, focusing on responses in airway cells and activated immune cells. I will then selectively block specific miRNAs to determine effects on disease severity and cell function, with the aim to identify novel therapies for asthma treatment. Ultimately, our aim is to bring these findings into the clinic and provide a new therapy to treat patients suffering from steroid-resistant asthma.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maltby, Steven
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~